CD274 and neoplasm: The combination of HER2-specific CAR-T cells with CAd-VECPDL1 showed improved anti-tumor activity and controlled tumor growth significantly better than either PD-L1 antibody or CAR-T cells alone in an HER2(+) prostate cancer xenograft model (86).